48,900 Shares in Twist Bioscience Co. (NASDAQ:TWST) Acquired by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 48,900 shares of the company's stock, valued at approximately $2,272,000. Canada Pension Plan Investment Board owned approximately 0.08% of Twist Bioscience at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Stifel Financial Corp increased its position in shares of Twist Bioscience by 11.8% in the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company's stock valued at $315,000 after acquiring an additional 734 shares during the period. Barclays PLC increased its holdings in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the third quarter worth about $34,000. Franklin Resources Inc. lifted its holdings in shares of Twist Bioscience by 3.4% during the third quarter. Franklin Resources Inc. now owns 252,064 shares of the company's stock worth $11,756,000 after purchasing an additional 8,308 shares during the period. Finally, Beaird Harris Wealth Management LLC purchased a new stake in Twist Bioscience in the third quarter valued at approximately $95,000.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares in the company, valued at approximately $965,531.49. This trade represents a 13.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Dennis Cho sold 806 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares in the company, valued at $5,538,106.35. The trade was a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,374 shares of company stock valued at $955,871 over the last ninety days. Insiders own 3.01% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research note on Friday, March 28th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday, February 4th. Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 4th. Finally, Barclays cut their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and an average price target of $52.80.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $37.62 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The firm has a market cap of $2.24 billion, a PE ratio of -11.13 and a beta of 2.34. Twist Bioscience Co. has a one year low of $29.76 and a one year high of $60.90. The firm has a fifty day moving average of $39.95 and a 200 day moving average of $44.28.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the firm earned ($0.75) EPS. The company's revenue for the quarter was up 24.1% on a year-over-year basis. As a group, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.